The United States Court of Appeals for the Second Circuit recently revived a whistleblower lawsuit against Novartis,  marking a development in the enforcement of the Anti-Kickback Statute (AKS). This decision broadened the scope of what constitutes a violation under the AKS, specifically impacting how pharmaceutical companies conduct speaker…